This review focuses on the posttranslational acetylation of non-histone proteins, which
determines vital regulatory processes. The recruitment of histone acetyltransferases and …

In addition to well-characterized genetic abnormalities that lead to cancer onset and
progression, it is now recognized that alterations to the epigenome may also play a …

HER2 is a transmembrane oncoprotein encoded by the HER2/neu gene and is
overexpressed in approximately 20 to 25% of invasive breast cancers. It can be …

Purpose: The aim was to study the biological and molecular effects of the histone
deacetylase (HDAC) inhibitor, valproic acid, in patients with solid tumor malignancies …

Purpose: This study is aimed at investigating antineoplastic efficacy of histone deacetylase
inhibitor (HDACI) LBH589 on renal cell carcinoma (RCC) and elucidating the novel …

More than 60 years after the first description of differentiation in cell culture and 40 years
after the synthesis of 5-azacytidine, epigenetic therapies have been added to the anticancer …

Histone proteins are subject to a diverse range of post-translational modifications which,
along with DNA methylation, play a major role in controlling gene expression, cell division …

Abstract Purpose: Histone deactylase inhibitors (HDACi) are a promising new class of
anticancer therapeutics; however, little is known about HDACi activity in soft tissue sarcoma …

Breast cancer is a highly heterogeneous disease with distinct histologic subtypes. Targeted
therapies such as endocrine therapy and growth factor receptor inhibitors have had a …

HER2 is a transmembrane tyrosine kinase receptor in the EGFR (epidermal growth factor
receptor) family. The role of HER2 has been most thoroughly studied in breast cancer, in …